blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2950788

EP2950788 - COMPOSITION COMPRISING A TNFR AGONIST AND AT LEAST ONE THIOREDOXIN INHIBITOR FOR USE IN THE TREATMENT OF CARCINOMA. [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.11.2019
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  07.12.2018
FormerGrant of patent is intended
Status updated on  09.08.2018
FormerExamination is in progress
Status updated on  07.04.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
University of Huddersfield
Queensgate, Huddersfield HD1 3DH / GB
[2015/50]
Inventor(s)01 / GEORGOPOULOS, Nikolaos
c/o University of Huddersfield
Queensgate
Huddersfield West Yorkshire HD1 3DH / GB
 [2015/50]
Representative(s)Stephenson, Philip
Bailey Walsh & Co LLP
1 York Place
Leeds, LS1 2DR / GB
[2015/50]
Application number, filing date14705856.404.02.2014
[2015/50]
WO2014GB50305
Priority number, dateGB2013000192804.02.2013         Original published format: GB 201301928
GB2013001034911.06.2013         Original published format: GB 201310349
[2015/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014118578
Date:07.08.2014
Language:EN
[2014/32]
Type: A1 Application with search report 
No.:EP2950788
Date:09.12.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 07.08.2014 takes the place of the publication of the European patent application.
[2015/50]
Type: B1 Patent specification 
No.:EP2950788
Date:09.01.2019
Language:EN
[2019/02]
Search report(s)International search report - published on:EP07.08.2014
ClassificationIPC:A61K45/06, A61K31/00, A61K31/4164, A61K31/428, A61P35/00, A61K38/00, A61K38/17
[2018/33]
CPC:
A61K31/4164 (EP,US); A61K31/428 (EP,US); A61K38/005 (EP,US);
A61K38/1793 (EP,US); A61K38/191 (EP,US); A61K39/3955 (US);
A61K45/06 (EP,US); A61P35/00 (EP); C07K14/70575 (US);
C07K16/241 (US); C07K16/2875 (EP,US); C07K16/2878 (EP,US);
A61K2039/505 (EP,US); A61K31/10 (EP,US); C07K2317/75 (EP,US) (-)
C-Set:
A61K31/4164, A61K2300/00 (EP,US);
A61K31/428, A61K2300/00 (US,EP);
A61K38/005, A61K2300/00 (US,EP);
A61K38/1793, A61K2300/00 (US,EP)
Former IPC [2015/50]A61K31/00, A61K31/4164, A61K31/428, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/50]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZUSAMMENSETZUNG MIT EINEM TNFR-AGONISTEN UND MINDESTENS EINEM THIOREDOXIN-INHIBITOR ZUR BEHANDLUNG VON KARZINOMEN[2015/50]
English:COMPOSITION COMPRISING A TNFR AGONIST AND AT LEAST ONE THIOREDOXIN INHIBITOR FOR USE IN THE TREATMENT OF CARCINOMA.[2015/50]
French:COMPOSITION COMPRENANT UN AGONISTE DE TNFR ET AU MOINS UN INHIBITEUR DE THIORÉDOXINE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT D'UN CARCINOME[2015/50]
Entry into regional phase01.09.2015National basic fee paid 
01.09.2015Designation fee(s) paid 
01.09.2015Examination fee paid 
Examination procedure01.09.2015Examination requested  [2015/50]
11.03.2016Amendment by applicant (claims and/or description)
10.04.2017Despatch of a communication from the examining division (Time limit: M06)
20.10.2017Reply to a communication from the examining division
10.08.2018Communication of intention to grant the patent
03.12.2018Fee for grant paid
03.12.2018Fee for publishing/printing paid
03.12.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  10.04.2017
Opposition(s)10.10.2019No opposition filed within time limit [2019/51]
Fees paidRenewal fee
26.01.2016Renewal fee patent year 03
15.12.2016Renewal fee patent year 04
19.01.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.02.2014
AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
MK09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE04.02.2019
LU04.02.2019
MT04.02.2019
BE28.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
[2022/31]
Former [2021/32]HU04.02.2014
AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE04.02.2019
LU04.02.2019
MT04.02.2019
BE28.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2021/26]AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE04.02.2019
LU04.02.2019
MT04.02.2019
BE28.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/29]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE04.02.2019
LU04.02.2019
MT04.02.2019
BE28.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/17]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE04.02.2019
LU04.02.2019
BE28.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/12]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
IE04.02.2019
LU04.02.2019
BE28.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/09]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SK09.01.2019
SM09.01.2019
IE04.02.2019
LU04.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/51]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SK09.01.2019
SM09.01.2019
LU04.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/49]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SK09.01.2019
LU04.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/48]AT09.01.2019
DK09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RS09.01.2019
LU04.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/47]AT09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RS09.01.2019
LU04.02.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/46]AT09.01.2019
ES09.01.2019
FI09.01.2019
HR09.01.2019
IT09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RS09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/39]ES09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
PL09.01.2019
RS09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/38]ES09.01.2019
FI09.01.2019
LT09.01.2019
PL09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
PT09.05.2019
Former [2019/37]ES09.01.2019
FI09.01.2019
LT09.01.2019
PL09.01.2019
NO09.04.2019
GR10.04.2019
PT09.05.2019
Former [2019/35]ES09.01.2019
FI09.01.2019
LT09.01.2019
PL09.01.2019
NO09.04.2019
PT09.05.2019
Former [2019/33]FI09.01.2019
LT09.01.2019
NO09.04.2019
PT09.05.2019
Cited inInternational search[Y]WO03004479  (CANCER REC TECH LTD [GB], et al) [Y] 1-12 * claims 97, 159, 160; example 2; p. 100, l. 1-2 for PX-12 *;
 [XYI]  - FREEMAN R E ET AL, "Role of thioredoxin-1 in apoptosis induction by alpha-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 580, no. 11, doi:10.1016/J.FEBSLET.2006.04.019, ISSN 0014-5793, (20060515), pages 2671 - 2676, (20060515), XP028030524 [X] 1-5,7-9,11 * abstract; p. 2672, col. 1, section 2.4 * [Y] 1-12 [I] 1-12

DOI:   http://dx.doi.org/10.1016/j.febslet.2006.04.019
 [Y]  - T. LIN ET AL, "2-Tellurium-bridged -cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF- B suppression", CARCINOGENESIS, (20110201), vol. 32, no. 2, doi:10.1093/carcin/bgq234, ISSN 0143-3334, pages 154 - 167, XP055110705 [Y] 1-12 * abstract *

DOI:   http://dx.doi.org/10.1093/carcin/bgq234
by applicant   - LIN ET AL., CARCINOGENESIS, (2010), vol. 32, page 154
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.